Overview

A Study to Assess the Long-term Safety and Efficacy of Erenumab (AMG 334) in Chronic Migraine Prevention.

Status:
Completed
Trial end date:
2017-05-26
Target enrollment:
Participant gender:
Summary
To assess the long-term safety and efficacy of erenumab.
Phase:
Phase 2
Details
Lead Sponsor:
Amgen
Treatments:
Erenumab